- Home
- CCEC vs EYPT Comparison
CCEC vs EYPT Comparison
Compare CCEC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CCEC | EYPT |
|---|---|---|
| Price | $18.91 | $14.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $25.50 | ★ $31.80 |
| AVG Volume (30 Days) | 5.2K | ★ 821.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $18.95 | N/A |
| Revenue Next Year | $43.14 | $863.07 |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.83 | $5.37 |
| 52 Week High | $24.83 | $19.11 |
Technical Indicators
Market Signals| Indicator | CCEC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 53.46 |
| Support Level | $18.56 | $12.59 |
| Resistance Level | $21.80 | $14.54 |
| Average True Range (ATR) | 0.87 | 0.68 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 68.86 | 82.62 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.